Not sure if this was already posted, but just read an article that Lilly's drug bamlanvimab (which got EUA in November) is not currently allowed to be used in covid cases in California, Arizona and Nevada because of concerns about its efficacy with a recurring variant there. The fact that Leronlimab works effectively on variants could ultimately become a very important distinction!